Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | RLN2 |
| Gene Name: | RLN2 |
| Protein Full Name: | Prorelaxin H2 |
| Alias: | bA12D24.1.1; bA12D24.1.2; H2; prorelaxin H2; REL1; REL2; relaxin 2; relaxin H2; relaxin, ovarian, of pregnancy; RLXH2 |
| Mass (Da): | 21040 |
| Number AA: | 185 |
| UniProt ID: | P04090 |
| Locus ID: | 6019 |
| COSMIC ID: | RLN2 |
| Gene location on chromosome: | 9p24.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.21 |
| Normal role description: | Plays a role in maintenance of myometrial quiescence, facilitation of uterine stromal remodeling during uterine growth, and promotion of cervical ripening at the onset of parturition. In normal prostate tissue RLN2 increases sperm motility. Diverse physiological functions in different tissues. Increased expression in prostate tumors. Associated with growth and metastasis in prostate, breast and thyroid cancers. |